We applaud the Interventional Radiology team at the CHUM for being the first centre in Canada to utilize the Angiodroid Automated Carbon Dioxide Angiography system (ACDA) in order to provide maximum safety and protection for their patients. Secondly, the Endovascular/Vascular team at the CHUM also has completed a number of advanced EVAR and FEVAR cases using the ACDA with minimal use of contrast. The Endovascular/Vascular group at the Jewish General Hospital were the next to use the Angiodroid system in Canada and are pursuing acquisition of the first permanent place of the system.

We look forward to expanding the use of CO2 as a primary imaging agent in venous and arterial procedures below the diaphragm complementing the use of contrast media across Canada in the near future.

RSK Medical Inc. is pleased to announce Health Canada regulatory approval of the Angiodroid Automated Carbon Dioxide Angiography (ACDA) system for use in venous and arterial procedures. This represents a major step in the safety of angiography vs. the use of contrast in patients with kidney disease or with a potential allergy to contrast media. CO2 can be safely used in the arterial system below the diaphragm and below the subclavian in the venous system.

The ACDA system provides comparable imaging while providing a significant reduction in the use of contrast for patient safety and significant financial savings to the Canadian healthcare system. Please contact your RSK Medical representative for further information.

RSK Medical is pleased to announce a nationwide distribution agreement with Mermaid Medical for their Angel® Catheter – the first FDA-cleared IVC filter approved for prophylactic use. With a unique design that ensures both immediate PE protection and guaranteed retrieval, the Angel® Catheter offers critical support during high-risk periods.

Mermaid Medical is a Danish company that distributes and develops medical devices primarily within interventional radiology and the vascular system.

Read more: Mermaid Medical’s website

We are pleased to announce our new nationwide distribution agreement with Meril Life Sciences for their interventional structural cardiology products.  The Myval Octacor THV will be our first Meril device offering unique and differentiated therapy which aligns well with our company philosophy.  The Myval Octacor device has been implanted in over 21,000 patients.  The Myval device is not approved for use in Canada at present.

Read more about The Myval Octacor THV.

RSK Medical Inc. is pleased to announce the representation of MONTAGE XT, a settable, resorbable, hemostatic bone putty manufactured by Abyrx Inc. for sternal closure after open heart surgery to be used with sternotomy wires and/or sternal plates.

This bioabsorbable polymer is Health Canada and FDA cleared with over 35,000 patient applications in cranial, spinal, and orthopedic procedures.

Packaged as two putties, it forms a uniform putty when mixed for at least 45 seconds, hardening within 4 minutes. It adheres and expands up to 10% into surrounding porosity, resorbing during bone remodeling over a year.

Dr. Paul Fedak et al. published “Novel hardening bone putty enhances sternal closure and accelerates postoperative recovery” in the Journal of Thoracic and Cardiovascular Surgery (2022) showing safety and feasibility, reduced pain scores, improved physical functional recovery and shorter hospital stays with cost benefits to the Canadian healthcare system.

Please contact your local RSK Medical Inc. representative or me personally if you require further information.

RSK Medical is pleased to announce a new nationwide distribution agreement with Occlutech (Sweden), a leading specialist of minimally invasive cardiac devices effective May 1st, 2024.  Occlutech has developed, manufactured and commercialized minimally invasive implants for over 20 years.  They offer a broad and proven portfolio designed to address Congenital Heart Disease, Stroke Prevention & Adult Intervention and Heart Failure with PFO, ASD and VSD devices.

Read more: Occlutech website

RSK Medical Inc. is pleased to announce the completion of the first 8 ANGIODROID CO2 Injector cases in Canada in Interventional Radiology at the Centre hospalitalier de l’Université de Montreal (CHUM) last week under the Health Canada Special Access program. A variety of patients received venous or arterial CO2 angiograms due to restrictions related to the use of contrast media.

Thank you to Drs. Bouchard, Therasse, Perrault, Amaral and the Radiology hospital administration and their full clinical team for their great support.

CO2 angiography is an effective alternative to iodine without the risk of further impairment of renal function providing excellent imaging, improved safety and saves costs by using less iodine accompanied by fewer related complications.

RSK Medical, distributors of the VENUS-MEDTECH’s Venus-P transcatheter pulmonary valve and delivery system is proud to announce the recent Class IV approval by Health Canada. Venus-P is a self-expanding multi-level support frame with a tri-leaflet pericardium tissue valve. The Venus-P represents a significant new offering for patients suitable for a transcatheter procedure. The valve itself is available in 5 different diameters in 25 mm and 30 mm lengths far exceeding the offerings of alternative suppliers.

RSK Medical has begun distribution of the “Pocket Press” for Cardiac Implantable Electronic Devices (CIED*) across Canada. This new modern pressure bandage is manufactured by Compress Innovations after significant experience in the wound and implantable cardiac rhythm devices industry. With significant CRM experience in the industry, we look forward to standardizing and improving the pressure dressing over devices to reduce the incidence of hematomas in this large group of patients.

The Pocket Press is pre-assembled with a standardized level of compression utilizing a 3-anchor design and a high density foam to maximize compression over the pocket. Please view the Virtual In-service video at the website: www.pressuredressings.com. We are pleased to provide a means of reducing the number of hematomas and therefore the further risk of infections in device patients.

We are very pleased to announce a distribution agreement across Canada for the P&F TRICVALVE TRANSCATHETER BICAVAL VALVES system. It is designed for the treatment of severe and symptomatic Tricuspid Regurgitation. The system consists of two self-expanding valves for the treatment of patients with hemodynamically relevant tricuspid insufficiency and caval reflux. The bioprostheses are implanted percutaneously into the inferior and superior vena cava without disturbing the native tricuspid valve. It is especially intended for use for patients who are not candidates for open surgical therapy.

The system does not yet have regulatory approval in Canada. The TRICVALVE system is approved for use in Europe (CE Mark) with now over 1,000 implants worldwide.